Explore Luminary’s pipeline
Cancer research doesn’t sit still. Neither does our research.
Our product pipeline focuses on underserved cancers and autoimmune disorders. We are aggressively pursuing our BAFF CAR-T and Universal Receptor therapies, both utilizing Allogeneic manufacturing platforms. Here is where we stand today.
| Program | Type | Indication | Research & Preclinical Development | Phase 1&2 | Pivotal |
|---|---|---|---|---|---|
| LMY-920 | BAFF CAR-T Autologous | B-cell Malignancies | |||
| LMY-921 | BAFF CAR-T Allogeneic | B-cell Malignancies | |||
| LMY-922 | BAFF CAR-T Allogeneic | Autoimmune Disorders | |||
| LMY-232 Multiple Targets |
NORTHSTAR Universal Receptor | Solid Tumors |
